Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo to Work Out Collaboration Plans Country by Country: Mr Shoda
July 7, 2008
- Sawai Aims at Achieving \100 Bil. Sales before Any Other Generic Company in Japan
July 7, 2008
- Otsuka Pharm. to Be Reorganized under New Holding Company
July 7, 2008
- Blopress Best-Selling Ethical Drug 4 Years in a Row
July 7, 2008
- Ethical Drugs Market Up to \8,136.3 Bil. in FY2007: IMS Japan
July 7, 2008
- More Attendants, Questions at Major Pharmas' Shareholders' Meetings
July 7, 2008
- R&D NEWS IN BRIEF
July 7, 2008
- BUSINESS NEWS IN BRIEF
July 7, 2008
- 7-Year Strategy for Hepatitis Calls For Radical Cure Rate of 70% for Hepatitis C
July 7, 2008
- English-Speaking Japanese Executives Earn up to 30% More than Non-English Speaking Colleagues: Survey
July 7, 2008
- Generic Anticancer Drugs Used in 16% of Hospitals with 100 or More Beds: Survey
July 7, 2008
- Gov't to Maintain Policy to Cut \1.1 Tril.
July 7, 2008
- Many Pharmacists Don't Explain Generics to Patients: Survey
July 7, 2008
- Introduce Reference Price System to Promote Use of Generics: Council
July 7, 2008
- GENERICS NEWS IN BRIEF
July 7, 2008
- Late-Stage Consultation Fee to Be Frozen
July 7, 2008
- Addition of Zetia More Effective Than Doubling Dose of Statins: Prof. Yamada
July 7, 2008
- FPMAJ Presents NHI Pricing System Reform Proposal to Chuikyo
July 7, 2008
- Only 20% of General Citizens Aware of HbA1c
July 7, 2008
- FDA Extends Review Period for Prasugrel: Daiichi Sankyo, Eli Lilly
July 7, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…